YJEFN3 (YjeF N-terminal domain-containing protein 3) has been identified as a tumor-associated antigen in prostate adenocarcinoma (PRAD), where its overexpression and mutations are linked to poor prognosis and altered immune cell infiltration (55). This evidence concerns the gene YJEFN3 and neoplasm.